NVDA
NVIDIA
-- 147.070 TSLA
Tesla
-- 415.110 ORCL
Oracle
-- 184.220 TEM
Tempus AI
-- 50.450 NFLX
Netflix
-- 953.990 
NEWS
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
Mec-V antitumor activity observed across 9 different mKRAS variants
Strong association of AXL expression by mKRAS NSCLC confirmed
Monday, 16th December at 8:00 am
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
Mec-V antitumor activity observed across 9 different mKRAS variants
Strong association of AXL expression by mKRAS NSCLC confirmed
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
6830
Followers
46
Following
74K
Visitors
Follow
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day